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Abstract
Background: Lanthanum carbonate (FOSRENOL
®) is an effective, well-tolerated phosphate binder. The ability of
lanthanum to reduce serum phosphorus levels to ≤5.5 mg/dL in patients with end-stage renal disease (ESRD) was
assessed in a clinical practice setting.
Methods: A 16-week, phase IV study enrolled 2763 patients at 223 US sites to evaluate the efficacy of lanthanum
carbonate in controlling serum phosphorus in patients with ESRD, and patient and physician satisfaction with, and
preference for, lanthanum carbonate after conversion from other phosphate-binder medications. Patients received
lanthanum carbonate prescriptions from physicians. These prescriptions were filled at local pharmacies rather than
obtaining medication at the clinical trial site. Changes from serum phosphorus baseline values were analyzed using
paired t tests. Patient and physician preferences for lanthanum carbonate versus previous medications were
assessed using binomial proportion tests. Satisfaction was analyzed using the McNemar test. Daily dose, tablet
burden, and laboratory values including albumin-adjusted serum calcium, calcium × phosphorus product, and
parathyroid hormone levels were secondary endpoints.
Results: Serum phosphorus control (≤5.5 mg/dL) was effectively maintained in patients converting to lanthanum
carbonate monotherapy; 41.6% of patients had controlled serum phosphate levels at 16 weeks. Patients and
physicians expressed markedly higher satisfaction with lanthanum carbonate, and preferred lanthanum carbonate
over previous medication. There were significant reductions in daily dose and daily tablet burden after conversion
to lanthanum carbonate.
Conclusions: Serum phosphorus levels were effectively maintained in patients converted from other phosphate-
binder medications to lanthanum carbonate, with increased satisfaction and reduced tablet burden.
Trial Registration: ClinicalTrials.gov: NCT0016012
Background
Uncontrolled serum phosphorus is strongly associated
with increased mortality in patients with end-stage renal
disease (ESRD) [1]. Because of this, the Kidney Disease
Outcomes Quality Initiative (KDOQI) proposed a target
serum phosphorus range of 3.5 to 5.5 mg/dL for ESRD
patients, which could be achieved by a combination of
dialysis, dietary restrictions, and adherence to phos-
phate-binder medication regimens [2].
Many patients receiving maintenance dialysis do not
achieve target serum phosphorus levels for a variety of
reasons, including the complexity of their medical con-
dition, poor adherence to dietary restrictions, and poor
adherence to phosphate-binder therapy [3]. Reasons for
nonadherence to medication regimens have been shown
to be complex and multifactorial [4-7], but the high
daily tablet burden associated with most phosphate-bin-
der medications may be a contributing factor [8,9].
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different medications daily for various comorbid condi-
tions. The complex dosing schedules that result may
reduce adherence to dosing regimens [10]. Any means
of simplifying treatment by reducing daily tablet burden
is theoretically a positive step toward improving phos-
phate control in patients with ESRD.
Lanthanum carbonate is a non-calcium phosphate bin-
der with proven efficacy in the treatment of hyperpho-
sphatemia in patients with ESRD [11,12]. In vitro
studies suggest that lanthanum carbonate has a stronger
affinity for phosphate ions compared with other binders
[13]. This potential for lower doses and fewer tablets
may facilitate improved patient adherence, thereby con-
tributing to reduced morbidity and mortality by improv-
ing serum phosphorus control rates.
This study assessed the efficacy of lanthanum carbo-
nate in patients with ESRD requiring treatment for
hyperphosphatemia in a clinical practice setting and
patient and physician satisfaction with, and preference
for, lanthanum carbonate compared with previous phos-
phate binders. Total daily dose and tablet burden of
lanthanum carbonate compared with previous phos-
phate-binder therapies and the safety and tolerability of
lanthanum carbonate treatment were also evaluated.
Methods
Patients
Adult patients (≥18 y) with ESRD requiring treatment
for hyperphosphatemia were included in this study.
Patients receiving any investigational agent within 30
days before screening were excluded, as were pregnant
or lactating women. Patients could withdraw from the
study at any time, but withdrawal was mandatory if they
developed intercurrent illness or an adverse event that
precluded further study participation, required an alter-
native phosphate binder, became pregnant, or if discon-
tinuation was recommended by the investigator. This
study was conducted in adherence with the ethical prin-
ciples set forth in the Declaration of Helsinki (1989) and
with local laws and regulations relevant to the use of
new therapeutic agents. The protocol was approved for
each center by an Institutional Review Board. All
patients provided written, informed consent before par-
ticipating in the study.
Study Design
This was an open-label, phase IV, multicenter study
conducted in the United States between January and
December 2005. There was an initial screening visit and
a 1-week observation period using existing phosphate-
binder therapy during which no dose modifications were
permitted. After the observation period, patients imme-
diately began a 12-week lanthanum carbonate titration
period without washout. At the end of the titration per-
iod, patients continued lanthanum carbonate treatment
during a 4-week maintenance period. A follow-up inter-
view (telephone or face-to-face) was conducted 30 days
after the last dose of study medication to identify emer-
gent serious adverse events.
Study Medication
The original formulation of lanthanum carbonate was
supplied by patients’ local pharmacies using the Trial-
Card
® prescription program (TrialCard Inc, Cary, NC,
USA); each card was study-specific and individually
coded. A prescription was required for medication dis-
bursement, and the physician was required to activate
the card at the baseline visit (at the beginning of the
titration period) and at visit 2 (beginning of the 4-wk
maintenance period). All patients, regardless of prior
therapy, received an initial daily dose of 1500 mg (250-
mg or 500-mg tablets) in divided doses with meals that
was adjusted, if necessary, in 2 to 3 weekly increments
of 750-mg per day, up to the recommended maximum
dose of 3750 mg per day to achieve serum phosphorus
levels within the KDOQI guidelines target range of 3.5
to 5.5 mg/dL [1.13-1.78 mmol/L]).
Assessments
The intent-to-treat (ITT) population included all
patients who received at least 1 dose of study medica-
tion and underwent at least 1 primary efficacy evalua-
tion. The primary objectives of the study were to
evaluate efficacy and patient and physician satisfaction
and preference. Predialysis serum phosphorus was mea-
sured at screening, at baseline visit, and at the end of
the titration (week 12) and maintenance (week 16) peri-
ods of lanthanum carbonate treatment. A questionnaire
that assessed satisfaction with phosphate-binder medica-
tion was completed by the patient and physician at base-
line and at weeks 12 and 16 using a 7-item
questionnaire for patients and a 6-item questionnaire
for physicians; questions were rated on a 4-point Likert
scale with answers ranging from “strongly agree” to
“strongly disagree.” For patients taking medication for
hyperphosphatemia before participating in the study, a
product preference questionnaire was completed by
patients and physicians to determine preference for
lanthanum carbonate or previous medication at weeks
12 and 16 using a 6-item questionnaire for patients and
a 7-item question for physicians that addressed various
aspects of treatment and overall preference.
Secondary endpoints included tablet burden and daily
dose of phosphate-binder medication. These 2 para-
meters were assessed for all patients at screening, at
baseline, weeks 12 and 16, and visits during which a
new prescription indicating ad i f f e r e n td a i l yd o s ea n d
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procedures. Serum parathyroid hormone (PTH), cor-
rected (ie, albumin-adjusted) serum calcium, and cal-
cium × phosphorus (Ca × P) product were also
measured at screening, baseline visit, and weeks 12 and
16 of treatment with lanthanum carbonate. These
laboratory assessments were also measured bimonthly at
visits during the 12-week titration period.
Safety assessments for all patients who received at
least 1 dose of study medication (safety population)
included continuous monitoring of adverse events,
which were evaluated with regard to onset, severity, out-
come, relationship to study medication, and action
taken. Serious adverse events were monitored up to 30
days after the last dose of study medication and were
followed up until the event resolved or became chronic
or stable. Laboratory assessments, including evaluation
of liver enzyme (alanine aminotransferase, aspartate
aminotransferase, gamma-glutamyl transpeptidase, total
alkaline phosphatase, and lactic dehydrogenase) levels,
were performed at screening and at weeks 12 and 16.
Statistical Analysis
All summaries were presented overall and also accord-
ing to patients’ previous phosphate binder use; phos-
phate binder naive, previous sevelamer HCL, calcium-
based or ‘other’ binders. All analyses used the ITT
population. Serum phosphorus, calcium, Ca × P pro-
duct, PTH, daily dose, and tablet burden were summar-
ized by visit within previous phosphate-binder therapy
groups and overall. Changes from baseline were ana-
lyzed within previous phosphate-binder therapy groups
and for the overall combined group using a paired t
test. Results are presented as mean ± standard error of
the mean (SEM).
Satisfaction and preference were summarized by visit
within previous treatment groups and groups combined.
Differences in satisfaction between baseline and week 12
and week 16 were analyzed using the McNemar test
after combining responses of “strongly agree/agree” and
“disagree/strongly disagree.” Preference for lanthanum
carbonate at weeks 12 and 16 was compared with pre-
ference for previous medication using a binomial pro-
portion test. Treatment compliance was measured
indirectly through questions provided on the physician
and patient satisfaction questionnaires ("patient compli-
ance,”“ rarely missed a dose,” and “easy to take
medication”).
Results
Patients
This study enrolled 2763 patients at 223 sites. A detailed
description of patient demographic characteristics is
provided in Table 1. In the safety population (n = 2643),
the most commonly reported reasons for study disconti-
nuation were AEs (11.5%), withdrawal of consent (7.9%),
and investigator decision (6.3%). All other reasons (alter-
nate binder, death, and lost to follow-up) were each
reported for < 3% of patients. Thirty-five (1.3%) patients
did not have data on whether they completed the study
or a recorded reason for withdrawal. The distribution of
reasons for discontinuation in the ITT population was
similar to that for the safety population.
In the ITT population (n = 2520) at baseline, there
were 105 (4.2%) patients naive to phosphate binder
treatment, 1045 (41.5%) patients treated with calcium
(all calcium-based products), 958 (38.0%) patients trea-
ted with sevelamer HCl, and 412 (16.3%) patients trea-
ted with ‘other’ (mostly combination) phosphate-binder
therapies. Demographic characteristics were similar for
each previous treatment group.
Serum Phosphorus
At baseline, mean serum phosphorus levels were 6.03 ±
0.04 mg/dL (ITT population). Overall, after converting
to lanthanum carbonate monotherapy, patients’ serum
phosphorus levels throughout the 16-week study were
similar to those achieved with treatment with their pre-
vious phosphate binder (Figure 1). The mean change
from baseline was −0.06 ± 0.05 mg/dL at week 12 and
0.02 ± 0.05 mg/dL at week 16. Similar results were seen
for the previous calcium, sevelamer, and ‘other’ treat-
ment groups. For the binder-naïve group, statistically
significant reductions were seen at weeks 12 and 16
(−0.41 ± 0.19 mg/dL and −0.62 ± 0.19 mg/dL at weeks
12 and 16 respectively). Similar proportions of patients
achieved serum phosphorus control (≤5.5 mg/dL) at
baseline (41.8%) and maintained control during treat-
ment with lanthanum carbonate overall and in each
treatment group (overall group: week 12, 44.9%; week
Table 1 Patient Demographics
Patients enrolled, N 2763
Safety population, n 2643
ITT population, n 2520
Patients completed, n (%) 1751 (69.5)
Patients discontinued prematurely, n (%) 747 (29.6)
Sex, n (%)
Men 1480 (58.7)
Women 1040 (41.3)
Age (years), mean (SD) 56.4 (14.3)
Race, n (%)
White 1355 (53.8)
Black 1006 (39.9)
Other 158 (6.3)
Median time on dialysis, y (range) 2.2 (0-27)
Diabetic, n (%) 1244 (49.4)
ITT = intent to treat.
Vemuri et al. BMC Nephrology 2011, 12:49
http://www.biomedcentral.com/1471-2369/12/49
Page 3 of 816, 41.6%). In the binder-naïve group the percentage
with phosphorous control increased from 36.5% at base-
line to 58.7% at week 12 and 50.6% at week 16. (Figure
2).
Satisfaction and Preference
Assessments of patient and physician satisfaction
revealed that satisfaction at 12 weeks and 16 weeks of
treatment with lanthanum carbonate was markedly
improved compared with baseline values when patients
were using their previous phosphate binder (Figures 3
and 4). Patient satisfaction was statistically significantly
greater after treatment with lanthanum for each of the
separate domains for which satisfaction was measured,
except for stomach sickness and experiencing other side
effects (significant at week 12 but not week 16). The
increase from baseline in overall satisfaction was greater
for physicians than for patients; similar increases in
satisfaction were observed at week 16 (data not shown).
Analysis of changes in satisfaction for patients who were
treated previously with sevelamer HCl or calcium-based
phosphate binders revealed similar overall percentage
changes. Overall physician satisfaction increased by 34%
and 29% (based on clinical observation) for patients who
were treated previously with calcium-based binders and
sevelamer HCl, respectively, after 12 weeks of treatment
with lanthanum carbonate. Overall patient satisfaction
increased by 14% and 18% for patients who were treated
previously with calcium-based binders and sevelamer
HCl, respectively.
Seventy-three percent of patients and 83% of physi-
cians participating in the study preferred lanthanum car-
bonate over previous phosphate-binder medication at
week 12 (Figure 5), with a similar trend at week 16. Sta-
tistically significant differences in preference compared
Figure 1 Serum Phosphorus Levels. Serum phosphorus levels at
baseline and after converting to treatment with lanthanum
carbonate (intent to treat population). SEM = standard error of the
mean. *Mostly combination therapies; patients naive to treatment
with phosphate binders (n = 105) are not shown.
Figure 2 Proportion of Patients With Controlled Serum
Phosphorus Levels. Percentage of patients with controlled serum
phosphorus levels at baseline and weeks 12 and 16 of treatment
with lanthanum carbonate (intent to treat population). Patients
naive to treatment with phosphate binders (n = 105) are not
shown. LC = lanthanum carbonate.
Figure 3 Patient Satisfaction. Change in patient satisfaction after
12 weeks of treatment with lanthanum carbonate (intent to treat
population). Patients responded positively with “agree” or “strongly
agree.” *P< 0.0001 from chi-square test on change from baseline.
Figure 4 Physician Satisfaction. Change in physician satisfaction
after 12 weeks of treatment with lanthanum carbonate (intent to
treat population). Physicians responded positively with “agree” or
“strongly agree.” *P< 0.0001 from chi-square test on change from
baseline for all parameters.
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for all domains encompassed within the preference
questionnaire, including the number of tablets, ease of
taking medication, symptom control, and adverse effects
for patients and available dosage forms, effectiveness,
adverse effects, and patient adherence for physicians.
Daily Dose and Tablet Burden
There were significant reductions for all previous treat-
ment groups in tablet burden (P<0 . 0 0 1 ;F i g u r e6 )a n d
d a i l yd o s e( P< 0.0001) at weeks 12 and 16 of treatment
with lanthanum carbonate. The mean daily dose was
significantly reduced from 7.2 g at baseline to 2.8 and
2.7 g at weeks 12 and 16, respectively (P< 0.0001).
Reductions in daily tablet burden at week 12 ranged
from 2.2 ± 0.15 pills for patients previously receiving
calcium-based therapy (week 12) to 8.4 ± 0.40 pills for
patients previously receiving ‘other’ treatments. Similar
reductions were seen at week 16.
For patients previously treated with calcium acetate,
sevelamer HCl, or ‘other’ there were significant (P<
0.0001) reductions in the dose of phosphate binder
required to maintain serum phosphorus control when
patients were converted to treatment with lanthanum
carbonate. The mean reductioni nt o t a ld a i l yd o s er a n -
ged from 2.6 g/d to 8.1 g/d. At week 12, the ‘others’
group had the greatest mean reduction of 8.1 g/d while
the calcium group had the lowest reduction of 2.6 g/d.
Similar reductions were seen at week 16. The mean
daily doses of lanthanum carbonate required to main-
tain serum phosphorus levels were similar across all 3
groups previously treated with phosphate binders,
despite the wide variation in previous doses. For exam-
ple, the mean ± SEM dose of calcium previously used
was 5.4 ± 0.09 g/d and the mean ± SEM dose of lantha-
num carbonate at week 12 was 2.7 ± 0.04 g/d. Those
patients previously treated with sevelamer received 2.8
± 0.04 g/d of lanthanum carbonate at week 12 com-
pared with 7.6 ± 0.12 g/d of sevelamer at baseline.
Serum phosphorus levels were stable from baseline
through week 16 for all groups despite the markedly
lower doses of lanthanum carbonate relative to previous
medication.
Laboratory Assessments
The changes in corrected Ca, Ca × P, and PTH from
baseline are presented in (Table 2). Overall there were
statistically significant decreases in the serum calcium
levels and the changes in Ca × P product were consis-
tent with this. There was a statistically significant
increase in PTH after a change to treatment with
lanthanum carbonate.
Safety and Tolerability of Converting to Lanthanum
Carbonate
The incidence of adverse events reported during the
study was consistent with the known safety profile for
lanthanum carbonate. Among patients in the safety
population, adverse events were reported by 952/2643
(36.0%) patients; 327 (12.4%) patients had adverse events
which led to discontinued study participation. Most
adverse events were mild or moderate, with severe
events reported by 12.1% of all patients. The most com-
mon adverse events included nausea (7.9%), diarrhea
(5.4%), and vomiting (5.0%). Of all adverse events, 12.1%
were considered probably related to treatment and 5.4%
were deemed possibly related to treatment. Serious
adverse events were reported by 14.9% of patients, most
Figure 5 Overall Medication Preference. Patient and physician
overall medication preference at week 12 of treatment with
lanthanum carbonate (intent to treat population). *P< 0.0001 from
binomial test procedure with null hypothesis; proportion = 0.5.
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study medication.
There were no statistically significant changes from
baseline in liver enzymes (except alkaline phosphatase).
For alkaline phosphatase, mean ± SD levels at screening
were 111.4 ± 77.9 U/L; increases from screening of 5.3
± 70.6 and 6.8 ± 74.8 U/L were observed at weeks 12
and 16, respectively. However, the clinical significance
of this result could not be determined because of the
large standard deviations.
Discussion
Hyperphosphatemia is a serious consequence of
advanced kidney failure. A majority of patients with
ESRD/stage 5 chronic kidney disease require a phos-
phate binder as part of their treatment regimen, and in
some treatment may be required as early as stage 3. In
the study described here, patients with ESRD were con-
verted from previous treatments to lanthanum carbonate
monotherapy in a clinical practice setting. Patients
received prescriptions for study medication from their
nephrologist and obtained lanthanum carbonate tablets
from local pharmacies. Compared with most other clini-
cal trials in which patients receive study medication at
the trial site, this study design more accurately repre-
sents routine clinical activities, thereby increasing the
applicability of the results to standard practice. The
study, however, did not include active comparator or
placebo arms, either of which may have strengthened
the results.
Patients were converted to lanthanum carbonate
monotherapy without a washout period from previous
phosphate-binder regimens, which consisted of calcium-
based phosphate binders (41.5%), sevelamer (38.0%),
‘other’ (combinations of different binders; 16.3%), and
binder naïve (4.2%), respectively. The conversion to
lanthanum carbonate (250-mg and 500-mg tablets)
resulted in maintenance of serum phosphorus levels.
The mean change from baseline was −0.06 ± 0.05 mg/
dL at week 12 and 0.02 ± 0.05 mg/dL at week 16. At
baseline, 41.8% of patients achieved the KDOQI-recom-
mended level of control (≤5.5 mg/dL); 44.9% and 41.6%
achieved control at treatment weeks 12 and 16, respec-
tively. Slightly fewer than half of patients achieved
serum phosphorus control, reflecting disease severity.
This illustrates the difficulty of attaining treatment tar-
gets in patients with ESRD, who frequently have comor-
bid conditions such as diabetes and hypertension.
Patients and physicians reported increases in their
levels of satisfaction after converting to treatment with
lanthanum carbonate. Physician satisfaction with
observed efficacy (control of hyperphosphatemia, clinical
observation) increased with lanthanum carbonate treat-
ment at week 12, even though control of serum phos-
phorus levels did not improve significantly over baseline
levels. Patients and physicians indicated a statistically
significant preference for lanthanum carbonate over pre-
vious phosphate-binder medications for the majority of
domains.
Tablet burden has been reported to influence patient
adherence with phosphate-binder therapy [8,9]. In a
study conducted at 3 dialysis units across the United
States, higher pill burden was associated with lower
health-related quality of life and was not found to
improve control of serum phosphate levels [14]. In the
current study, a careful evaluation of tablet burden and
daily dose was performed. Significant reductions were
observed for the total daily dose and tablet burden;
mean dose reductions ranged from 2.6 to 8.1 g/d
required to control serum phosphorus and the mean
reduction in overall daily tablet burden ranged from 2.2
to 8.4 pills per day at week 12, with similar results at
week 16. Although treatment with lanthanum carbonate
resulted in reduced tablet burden, comparable levels of
serum phosphorus control were maintained throughout
the study. This observation plus findings from Chiu et
al [14] suggest that although tablet burden may improve
treatment compliance and quality of life, lowering or
raising the number of pills does not necessarily influ-
ence phosphate levels. Depending on the previous phos-
phate-binder regimen, the patients in this study were
taking, on average, between 8 and 15 pills per day at
baseline, compared with an average of approximately 6
tablets daily of the original larger lanthanum carbonate
formulation (no longer manufactured) to control serum
phosphorus at study week 16. Although patients had a
wide dose range of previous medication at baseline, the
average daily dose of lanthanum carbonate required to
Table 2 Laboratory Values at Baseline and change from Baseline at Weeks 12 and 16 of Lanthanum Carbonate
Treatment (ITT Population)
Assessment Corrected Serum Ca,
mg/dL
Ca × P Product,
mg
2/dL
2
Biointact PTH,
pg/mL
Baseline 9.49 ± 0.06 56.16 ± 0.49 241.88 ± 7.15
LC change from baseline to week 12 −0.13 ± 0.06* −1.15 ± 0.62 59.19 ± 7.33*
LC change from baseline week 16 −0.09 ± 0.06 −0.30 ± 0.66 49.30 ± 7.70*
Ca = calcium; Ca × P = calcium × phosphorus; ITT = intent to treat; LC = lanthanum carbonate; PTH = parathyroid hormone.
All data are mean ± standard error of the mean. *P≤ 0.05.
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This dose of lanthanum carbonate (~3.0 g/d) will allow
for dosing of 1 tablet per meal with 1000 mg tablets
[15]. The large difference between the doses of lantha-
num carbonate and previous binders may be explained,
in part, by in vitro data that show that lanthanum car-
bonate binds phosphate ions with a higher affinity com-
pared with other phosphate binders [13]. In addition,
unlike sevelamer and calcium-based phosphate binders,
lanthanum carbonate binds phosphate within the entire
pH range found in the gastrointestinal tract [13].
Although this study demonstrates that lanthanum car-
bonate is effective at controlling serum phosphorus with
a reduced tablet burden in patients with ESRD, several
noteworthy limitations exist. The results from the study
would have been strengthened if an active comparator
arm or a placebo arm had been included. However, the
present study was designed to assess whether results
obtained from clinical trials of lanthanum carbonate
could be replicated in the clinical practice setting. The
use of the TrialCard system, in which patients receive
free medication, may have biased patient opinion when
comparing with previous medications that likely
required copayment. Physicians were compensated for
their time and involvement in this study, and thus, phy-
sician bias with regard to product preference and satis-
faction cannot be excluded. Lastly, patient compliance
with the treatment regimen was not stringently moni-
tored. However, indirect measures of compliance, such
as improved patient satisfaction associated with easy to
use study medication (Figure 3) and rarely missing a
dose (Figure 3), as well as improved physician satisfac-
tion with compliance (Figure 4), suggest that patient
compliance was not a significant issue.
Although there was no comparator arm in this study,
the efficacy and tolerability of lanthanum carbonate
have been well documented in previous studies
[11,12,16-18]. Changes in Ca × P product were consis-
tent with statistically significant decreases in the serum
calcium levels. There was a statistically significant
increase in PTH after a change to treatment with
lanthanum carbonate, thus it is reasonable to suggest
that the increase in alkaline phosphatase observed at
weeks 12 and 16 may have been due to normalization of
bone formation rate (ie, increased bone alkaline phos-
phatase fraction).
Conclusions
Lanthanum carbonate monotherapy offers effective
serum phosphorus control comparable to that of other
phosphate binders, with a reduced daily dose and tablet
burden for the patient compared with other phosphate
binders, including sevelamer HCl and calcium salts, as
monotherapy or in combination. Conversion to
treatment with lanthanum carbonate from other phos-
phate binders resulted in improved patient and physi-
cian satisfaction. The majority of patients and physicians
preferred treatment with lanthanum carbonate over pre-
vious treatment with phosphate binders. Lanthanum
carbonate may offer advantages in the treatment of
hyperphosphatemia in ESRD by reducing tablet burden,
which translates into a simplified dosing regimen that
may have a positive impact on patient adherence and
rates of serum phosphorus control in the clinic. Addi-
tionally, this reduction in tablet burden with lanthanum
carbonate may positively impact adherence with other
nonbinder medications prescribed for ESRD patients,
who often are managing other comorbid conditions.
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